Correction for Suerbaum et al., “Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model”

Suerbaum, Sebastian; Coombs, Nina; Patel, Lubna; Pscheniza, Dimitri; Falk, Christine S.; Gruber, Achim D.; Kershaw, Olivia; Chhatwal, Patrick; Brönstrup, Mark; Bilitewski, Ursula; Josenhans, Christine

doi:10.1128/mbio.02301-22

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to research by Liang Yang et al, hydroxycoumarins may exert antibacterial effects by inhibiting the formation of Ralstonia solanacearum biofilms through the downregulation of flagellar genes fliA and flhC (Yang et al, 2016). Research by Sebastian Suerbaum et al resulted in the development of a system for screening inhibitors of H. pylori flagellar biosynthesis and the discovery of a series of new antibacterial drugs (Suerbaum et al, 2022). Rongrong He et al found that linalool emulsion could interact with the flagellar cap protein (FliD) and DNA of Pseudomonas aeruginosa, inhibiting biofilm formation and causing P. aeruginosa death (He et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

“…For instance, silver ions and silver nanoparticles induce irreversible alterations in flagella structure, impairing movement and causing cell death (Li et al, 2017). In the case of H. pylori, β-lapachone exhibits remarkable bactericidal activity and anti-motility activity by specifically targeting the flagella (Suerbaum et al, 2022). Likewise, ferulic acid and p-coumaric display potent anti-Salmonella Enteritidis activity and significant antibiofilm effects, primarily due to their strong affinity for flagella proteins (Xu et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Vibrio parahaemolyticus compounds from Streptomyces parvus based on Pan-genome and subtractive proteomics

Liu

Tian

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionVibrio parahaemolyticus is a foodborne pathogen commonly found in seafood, and drug resistance poses significant challenges to its control. This study aimed to identify novel drug targets for antibacterial drug discovery.MethodsTo identify drug targets, we performed a pan-genome analysis on 58 strains of V. parahaemolyticus genomes to obtain core genes. Subsequently, subtractive proteomics and physiochemical checks were conducted on the core proteins to identify potential therapeutic targets. Molecular docking was then employed to screen for anti-V. parahaemolyticus compounds using a in-house compound library of Streptomyces parvus, chosen based on binding energy. The anti-V. parahaemolyticus efficacy of the identified compounds was further validated through a series of experimental tests.Results and DiscussionPangenome analysis of 58 V. parahaemolyticus genomes revealed that there were 1,392 core genes. After Subtractive proteomics and physiochemical checks, Flagellar motor switch protein FliN was selected as a therapeutic target against V. parahaemolyticus. FliN was modeled and docked with Streptomyces parvus source compounds, and Actinomycin D was identified as a potential anti-V. parahaemolyticus agent with a strong binding energy. Experimental verification confirmed its effectiveness in killing V. parahaemolyticus and significantly inhibiting biofilm formation and motility. This study is the first to use pan-genome and subtractive proteomics to identify new antimicrobial targets for V. parahaemolyticus and to identify the anti-V. parahaemolyticus effect of Actinomycin D. These findings suggest potential avenues for the development of new antibacterial drugs to control V. parahaemolyticus infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Anti-Vibrio parahaemolyticus compounds from Streptomyces parvus based on Pan-genome and subtractive proteomics

Liu

Tian

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…compound exhibits potential as an adjunct to the conventional antibiotic-based combination therapy for the treatment and eradication of H. pylori infection (Suerbaum et al, 2022).…”

Section: Pathogenesis 31 Colonizationmentioning

confidence: 99%

Helicobacter pylori infection: a dynamic process from diagnosis to treatment

Sun,

Yuan,

Zhou

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Helicobacter pylori, a gram-negative microaerophilic pathogen, causes several upper gastrointestinal diseases, such as chronic gastritis, peptic ulcer disease, and gastric cancer. For the diseases listed above, H. pylori has different pathogenic mechanisms, including colonization and virulence factor expression. It is essential to make accurate diagnoses and provide patients with effective treatment to achieve positive clinical outcomes. Detection of H. pylori can be accomplished invasively and noninvasively, with both having advantages and limitations. To enhance therapeutic outcomes, novel therapeutic regimens, as well as adjunctive therapies with probiotics and traditional Chinese medicine, have been attempted along with traditional empiric treatments, such as triple and bismuth quadruple therapies. An H. pylori infection, however, is difficult to eradicate during treatment owing to bacterial resistance, and there is no commonly available preventive vaccine. The purpose of this review is to provide an overview of our understanding of H. pylori infections and to highlight current treatment and diagnostic options.

show abstract

Correction for Suerbaum et al., “Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model”

Cited by 2 publications

References 0 publications

Anti-Vibrio parahaemolyticus compounds from Streptomyces parvus based on Pan-genome and subtractive proteomics

Anti-Vibrio parahaemolyticus compounds from Streptomyces parvus based on Pan-genome and subtractive proteomics

Helicobacter pylori infection: a dynamic process from diagnosis to treatment

Contact Info

Product

Resources

About